CLDX — CELLDEX THERAPEUTICS INC NEW

Ownership history in BRAIDWELL LP  ·  2 quarters on record

This page tracks every 13F SEC filing in which BRAIDWELL LP reported a position in CELLDEX THERAPEUTICS INC NEW (CLDX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.61% (2025 Q4)
Avg. % of fund
1.03%
First filed
2025 Q3
Last filed
2025 Q4
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 1,858,109 +1,266,420 +214.0% 1.61% $50.5M $27.16
2025 Q3 INITIATED 591,689 — — 0.45% $15.3M $25.87
% of Fund (quarterly)    CLDX price (monthly, adj. close)

Other funds also holding CLDX

As of 2025 Q4 — sorted by position size

Kynam Capital Management, LP 3Y 10.31% Elmind Capital, LP 6.93% Commodore Capital LP 3Y 4.64% 5AM Venture Management, LLC 3Y 4.25% Propel Bio Management, LLC 3.58% GordonMD Global Investments LP 3.32% Novo Holdings A/S 3Y 7Y 2.53% TSP Capital Management Group, LLC 3Y 7Y 2.49% Eversept Partners, LP 3Y 7Y 1.96% Bellevue Group AG 3Y 7Y 1.86%
← Back to BRAIDWELL LP Holdings